AAAAAA

   
Results: 1-23 |
Results: 23
Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene
Authors: Rombouts, WJC Lowenberg, B van Putten, WLJ Ploemacher, RE
Citation: Wjc. Rombouts et al., Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene, LEUKEMIA, 15(7), 2001, pp. 1046-1053
The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial
Authors: Creutzberg, CL van Putten, WLJ Koper, PC Lybeert, MLM Jobsen, JJ Warlam-Rodenhuis, CC De Winter, KAJ Lutgens, LCHW van den Bergh, ACM van der Steen-Banasik, E Beerman, H van Lent, M
Citation: Cl. Creutzberg et al., The morbidity of treatment for patients with stage I endometrial cancer: Results from a randomized trial, INT J RAD O, 51(5), 2001, pp. 1246-1255
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Authors: Meijers-Heijboer, H van Geel, B van Putten, WLJ Henzen-Logmans, SC Seynaeve, C Menke-Pluymers, MBE Bartels, CCM Verhoog, LC van den Ouweland, AMW Niermeijer, MF Brekelmans, CTM Klijn, JGM
Citation: H. Meijers-heijboer et al., Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation., N ENG J MED, 345(3), 2001, pp. 159-164
Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease:more extended disease identified
Authors: Lugtenburg, PJ Krenning, EP Valkema, R Oei, HY Lamberts, SWJ Eijkemans, MJC van Putten, WLJ Lowenberg, B
Citation: Pj. Lugtenburg et al., Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease:more extended disease identified, BR J HAEM, 112(4), 2001, pp. 936-944
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
Authors: van der Kolk, DM de Vries, EGE van Putten, WLJ Verdonck, LF Ossenkoppele, GJ Verhoef, GEG Vellenga, E
Citation: Dm. Van Der Kolk et al., P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia, CLIN CANC R, 6(8), 2000, pp. 3205-3214
Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer
Authors: Bontenbal, M van Putten, WLJ Burghouts, JTM Baggen, MGA Ras, GJ Stiegelis, WF Beudeker, M Janssen, JTP Braun, JJ van der Linden, GHM van der Velden, PC van Geel, AN Helle, P Leisink, M Foekens, JA Klijn, JGM
Citation: M. Bontenbal et al., Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer, J CL ONCOL, 18(4), 2000, pp. 734-742
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
Authors: Creutzberg, CL van Putten, WLJ Koper, PCM Lybeert, MLM Jobsen, JJ Warlam-Rodenhuis, CC De Winter, KAJ Lutgens, LCHW van den Bergh, ACM van de Steen-Banasik, E Beerman, H van Lent, M
Citation: Cl. Creutzberg et al., Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial, LANCET, 355(9213), 2000, pp. 1404-1411
Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial
Authors: van der Zee, J Gonzalez, DG van Rhoon, GC van Dijk, JDP van Putten, WLJ Hart, AAM
Citation: J. Van Der Zee et al., Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial, LANCET, 355(9210), 2000, pp. 1119-1125
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
Authors: Berns, EMJJ Foekens, JA Vossen, R Look, MP Devilee, P Henzen-Logmans, SC van Staveren, IL van Putten, WLJ Inganas, M Meijer-van Gelder, ME Cornelisse, C Claassen, CJC Portengen, H Bakker, B Klijn, JGM
Citation: Emjj. Berns et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, CANCER RES, 60(8), 2000, pp. 2155-2162
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
Authors: Foekens, JA Peters, HA Look, MP Portengen, H Schmitt, M Kramer, MD Brunner, N Janicke, F Meijer-van Gelder, ME Henzen-Logmans, SC van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, CANCER RES, 60(3), 2000, pp. 636-643
Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy
Authors: van Lom, K Houtsmuller, AB van Putten, WLJ Slater, RM Lowenberg, B
Citation: K. Van Lom et al., Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy, GENE CHROM, 25(4), 1999, pp. 332-338
A randomized study of granulocyte colony-stimulating factor applied duringand after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group
Authors: Ossenkoppele, GJ van der Holt, B Verhoef, GEG Daenen, SMGJ Verdonck, LF Sonneveld, P Wijermans, PW van der Lelie, J van Putten, WLJ Lowenberg, B
Citation: Gj. Ossenkoppele et al., A randomized study of granulocyte colony-stimulating factor applied duringand after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group, LEUKEMIA, 13(8), 1999, pp. 1207-1213
Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomizedstudy
Authors: Koper, PCM Stroom, JC van Putten, WLJ Korevaar, GA Heijmen, BJM Wijnmaalen, A Jansen, PP Hanssens, PEJ Griep, C Krol, ADG Samson, MJ Levendag, PC
Citation: Pcm. Koper et al., Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomizedstudy, INT J RAD O, 43(4), 1999, pp. 727-734
Comparison of the clinical effectiveness of the 433 MHz lucite cone applicator with that of a conventional waveguide applicator in applications of superficial hyperthermia
Authors: Rietveld, PJM van Putten, WLJ van der Zee, J van Rhoon, GC
Citation: Pjm. Rietveld et al., Comparison of the clinical effectiveness of the 433 MHz lucite cone applicator with that of a conventional waveguide applicator in applications of superficial hyperthermia, INT J RAD O, 43(3), 1999, pp. 681-687
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study
Authors: Pronk, LC van Putten, WLJ van Beurden, V de Boer-Dennert, M Stoter, G Verweij, J
Citation: Lc. Pronk et al., The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study, CANC CHEMOT, 43(2), 1999, pp. 173-177
Peripheral blood stem cell transplantation as an alternative to autologousmarrow transplantation in the treatment of acute myeloid leukemia?
Authors: Vellenga, E van Putten, WLJ Boogaerts, MA Daenen, SMGJ Verhoef, GEG Hagenbeek, A Jonkhoff, AR Huijgens, PC Verdonck, LF van der Lelie, J Schouten, HC Gmur, J Wijermans, P Gratwohl, A Hess, U Fey, MF Lowenberg, B
Citation: E. Vellenga et al., Peripheral blood stem cell transplantation as an alternative to autologousmarrow transplantation in the treatment of acute myeloid leukemia?, BONE MAR TR, 23(12), 1999, pp. 1279-1282
Ischemic heart disease after mantlefield irradiation for Hodgkin's diseasein long-term follow-up
Authors: Reinders, JG Heijmen, BJM Olofsen-van Acht, MJJ van Putten, WLJ Levendag, PC
Citation: Jg. Reinders et al., Ischemic heart disease after mantlefield irradiation for Hodgkin's diseasein long-term follow-up, RADIOTH ONC, 51(1), 1999, pp. 35-42
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
Authors: de Witte, JH Sweep, CGJ Klijn, JGM Grebenschikov, N Peters, HA Look, MP van Tienoven, TH Heuvel, JJTM van Putten, WLJ Benraad, TJ Foekens, JA
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients, BR J CANC, 79(7-8), 1999, pp. 1190-1198
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Authors: Foekens, JA Diamandis, EP Yu, H Look, MP Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer, BR J CANC, 79(5-6), 1999, pp. 888-894
Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation
Authors: van der Zee, J van der Holt, B Rietveld, PJM Helle, PA Wijnmaalen, AJ van Putten, WLJ van Rhoon, GC
Citation: J. Van Der Zee et al., Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation, BR J CANC, 79(3-4), 1999, pp. 483-490
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients
Authors: Foekens, JA Look, MP Bolt-de Vries, J Meijer-van Gelder, ME van Putten, WLJ Klijn, JGM
Citation: Ja. Foekens et al., Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810patients, BR J CANC, 79(2), 1999, pp. 300-307
Heterogeneous X inactivation in trophoblastic cells of human full-term female placentas
Authors: Looijenga, LHJ Gillis, AJM Verkerk, AJMH van Putten, WLJ Oosterhuis, JW
Citation: Lhj. Looijenga et al., Heterogeneous X inactivation in trophoblastic cells of human full-term female placentas, AM J HU GEN, 64(5), 1999, pp. 1445-1452
Uptake and distribution of doxorubicin in hormone-manipulated human breastcancer cells in vitro
Authors: Bontenbal, M Sieuwerts, AM Peters, HA van Putten, WLJ Foekens, JA Klijn, JGM
Citation: M. Bontenbal et al., Uptake and distribution of doxorubicin in hormone-manipulated human breastcancer cells in vitro, BREAST CANC, 51(2), 1998, pp. 139-148
Risultati: 1-23 |